Syra Health Corp. Class A Common Stock
NASDAQ: SYRA · HEALTHCARE · MEDICAL CARE FACILITIES
Updated 2026-06-05
Syra Health Corp. Class A Common Stock (SYRA) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for SYRA.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
SYRA historical valuation range
Where current P/E sits in SYRA's own 5Y range.
SYRA intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
SYRA valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.78x
Is SYRA overvalued in 2026?
Syra Health Corp. Class A Common Stock (SYRA) currently trades at $0.44 per share with a market capitalization of $5,886,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 29/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
SYRA currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.8x, the market is valuing the company primarily on its revenue rather than its earnings.
A standard DCF model does not produce reliable output for SYRA under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: SYRA appears richly valued on our framework, with a Smart Value Score of 29/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is SYRA overvalued?
SYRA scores 29/100 on our Smart Value Score (Grade F), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is SYRA's fair value?
A standard DCF is unreliable for SYRA given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does SYRA trade at?
SYRA does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is SYRA a buy based on valuation?
Our Smart Value rating for SYRA is Strong Sell, from a Smart Value Score of 29/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does SYRA's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on SYRA.
What is SYRA's Smart Value Score?
SYRA's Smart Value Score is 29/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.